News | February 04, 2026
Zydus Wellness net sales up by 113.7% in Q3 FY26
Glucon-D maintained its leadership position with a 59% MAT market share
Glucon-D maintained its leadership position with a 59% MAT market share
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The base Gland business posted ?11,790 million in revenue, up 16% YoY
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
Subscribe To Our Newsletter & Stay Updated
